Khaled Abdul Nour, MD
Cardiovascular Disease · Detroit, MINPI 1184792608
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,225 of the $9,621 with a category attached, or 95.9%. Siemens Medical Solutions USA, Inc. accounts for 95.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $7,972 and has fallen 98.4% since, to $130 in 2024.
Across 17 payments — averaging $565.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$9K
- Novo Nordisk$241
- Philips North America LLC$96
- Amgen$60
Across 91 payments — averaging $7993.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$397K
- Eli Lilly$171K
- Amgen$106K
- AstraZeneca$41K
- E.r. Squibb & Sons, L.L.C.$5K
- Merck$4K
- plus $1K from 1 others
What the payments were for
- Consulting fees$9,22596%
- Food & beverage$3644%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 9 | $9,225 |
| Novo Nordisk | 3 | $241 |
| Philips North America LLC | 1 | $96 |
| Amgen | 4 | $60 |
How this compares
$9,621 in reported general payments places this provider in the 75th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 159 | $195,101 |
| EntrestoSacubitril/Valsartan | 25 | $31,588 |
| Repatha SyringeEvolocumab | 30 | $25,752 |
| XareltoRivaroxaban | 21 | $24,130 |
| JardianceEmpagliflozin | 22 | $22,617 |
| Repatha SureclickEvolocumab | 19 | $22,297 |
| Atorvastatin Calcium | 307 | $4,716 |
| Metoprolol Succinate | 158 | $2,910 |
| Bumetanide | 43 | $2,194 |
| Labetalol Hcl | 13 | $2,096 |
| Losartan Potassium | 157 | $1,804 |
| Carvedilol | 102 | $1,563 |
| Nifedipine ErNifedipine | 46 | $1,535 |
| Rosuvastatin Calcium | 80 | $1,487 |
| Furosemide | 112 | $1,012 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Detroit
- Pedro Villablanca SpinettoDetroit$620K
- Wayne WeaverDetroit$340K
- Brian OneillDetroit$250K
- Karthikeyan AnanthasubramaniamDetroit$112K
- Gerald KoenigDetroit$96K
- David LanfearDetroit$82K
- Celeste WilliamsDetroit$70K
- Mahir ElderDetroit$68K
- Cori RussellDetroit$67K
- Pedro Engel GonzalezDetroit$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.